Korea's LG Life Sciences Teams with Macrogen to Pool Genetics Databases for Personalized Medicines and Theranostics
This article was originally published in PharmAsia News
Executive Summary
SEOUL - South Korea's LG Life Sciences hopes to bring new life to its stalled oncology program by inking a memorandum of understanding with genomic services provider Macrogen to work together for the development and commercialization of personalized medicine using patients' genetic information
You may also be interested in...
LG Life Sciences' 2nd Quarter Sales Dampened By Strong Won, Tightened Regulatory Watch On Pharma
SEOUL - The ongoing appreciation of the Korean won vs. the U.S. dollar and a tighter government grip on pharmas to detect malpractices such as rebates - or kickbacks - in the local pharma industry adversely affected the second quarter earnings of LG Life Sciences
LG Life Sciences-Green Cross Tie-up Might Not Trigger Matching Alliances By Other Korean Drug Makers
SEOUL - A recent deal covering cooperation in domestic and global sales between South Korea's second largest pharmaceutical company, Green Cross, and 10-ranked LG Life Sciences has not yet triggered any similar tie-ups by other major drug players
PharmAsia News Business Bulletin
A regular roundup of commercial stories appearing in Scrip’s sister publication PharmAsia News, whose multilingual team of regional experts provides authoritative business intelligence focused on the Asian marketplace. Full stories can be accessed by clicking on the story title (subscription required).